BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37980224)

  • 1. Anticoagulation prophylaxis patterns following retroperitoneal lymph node dissection for testis cancer.
    D'Andrea V; Jason Qian Z; Yim K; Egan J; Magnani CJ; Feldman A; Salari K; Tewari A; Steele G; Mossanen M; Preston M; Chang SL; Clinton TN
    Urol Oncol; 2023 Dec; 41(12):489.e1-489.e6. PubMed ID: 37980224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.
    Woldu SL; Moore JA; Ci B; Freifeld Y; Clinton TN; Aydin AM; Singla N; Laura-Maria K; Hutchinson RC; Amatruda JF; Sagalowsky A; Lotan Y; Arriaga Y; Margulis V; Xie Y; Bagrodia A
    Eur Urol Oncol; 2018 Aug; 1(3):242-251. PubMed ID: 31058267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group.
    Gerdtsson A; Håkansson U; Törnblom M; Jancke G; Negaard HFS; Glimelius I; Halvorsen D; Karlsdóttir Á; Haugnes HS; Andreassen KE; Larsen SM; Holmberg G; Wahlqvist R; Tandstad T; Cohn-Cedermark G; Ståhl O; Kjellman A
    Eur Urol Oncol; 2020 Jun; 3(3):382-389. PubMed ID: 31506250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midline Extraperitoneal Approach to Retroperitoneal Lymph Node Dissection in Testicular Cancer: Minimizing Surgical Morbidity.
    Syan-Bhanvadia S; Bazargani ST; Clifford TG; Cai J; Miranda G; Daneshmand S
    Eur Urol; 2017 Nov; 72(5):814-820. PubMed ID: 28325537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
    Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
    Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
    [No Abstract]   [Full Text] [Related]  

  • 6. Robot-assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer: Evolution of the Technique.
    Stepanian S; Patel M; Porter J
    Eur Urol; 2016 Oct; 70(4):661-667. PubMed ID: 27068395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients.
    Nicolai N; Cattaneo F; Biasoni D; Catanzaro M; Torelli T; Zazzara M; Necchi A; Giannatempo P; Raggi D; Piva L; Colecchia M; Salvioni R; Stagni S
    J Endourol; 2016 Oct; 30(10):1112-1119. PubMed ID: 27533924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trans- and extraperitoneal retroperitoneal lymph node dissection (RPLND) in the treatment for nonseminomatous germ cell testicular tumors (NSGCT): a single Chinese center's retrospective analysis.
    Tong S; Chen M; Zu X; Li Y; He W; Lei Y; Liu W; Qi L
    Int Urol Nephrol; 2014 Feb; 46(2):363-9. PubMed ID: 23996573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
    Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
    Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Robot-assisted Retroperitoneal Lymph Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multi-institutional Cohort.
    Taylor J; Becher E; Wysock JS; Lenis AT; Litwin MS; Jipp J; Langenstroer P; Johnson S; Bjurlin MA; Tan HJ; Lane BR; Huang WC
    Eur Urol Focus; 2021 Nov; 7(6):1403-1408. PubMed ID: 32682794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer.
    Pearce SM; Golan S; Gorin MA; Luckenbaugh AN; Williams SB; Ward JF; Montgomery JS; Hafez KS; Weizer AZ; Pierorazio PM; Allaf ME; Eggener SE
    Eur Urol; 2017 Mar; 71(3):476-482. PubMed ID: 27234998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing the Morbidity of Postchemotherapy Retroperitoneal Lymph Node Dissection for Testis Cancer in a National Cohort of Privately Insured Patients.
    Macleod LC; Rajanahally S; Nayak JG; Parent BA; Ramos JD; Schade GR; Holt SK; Dash A; Gore JL; Lin DW
    Urology; 2016 May; 91():70-6. PubMed ID: 26802801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major complications of post-chemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature.
    Ruf CG; Krampe S; Matthies C; Anheuser P; Nestler T; Simon J; Isbarn H; Dieckmann KP
    World J Surg Oncol; 2020 Sep; 18(1):253. PubMed ID: 32972425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laparoscopic retroperitoneal lymph node dissection for low-stage cancer: a Washington University update.
    Gardner MW; Roytman TM; Chen C; Brandes SB; Kibel AS; Grubb RL; Bhayani SB; Figenshau RS
    J Endourol; 2011 Nov; 25(11):1753-7. PubMed ID: 21936630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of retroperitoneal lymph node dissection for testicular cancer in the United States: Results from the National Cancer Database (1998-2011).
    Hugen CM; Hu B; Jeldres C; Burton C; Nichols CR; Porter CR; Daneshmand S
    Urol Oncol; 2016 Nov; 34(11):487.e7-487.e11. PubMed ID: 27372281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer.
    Mano R; Di Natale R; Sheinfeld J
    Urol Oncol; 2019 Mar; 37(3):209-218. PubMed ID: 30446455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer.
    Calaway AC; Einhorn LH; Masterson TA; Foster RS; Cary C
    Eur Urol; 2019 Nov; 76(5):607-609. PubMed ID: 31174891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacy.
    Nicolai N; Nazzani S; Tesone A; Macchi A; Piva L; Salvioni R; Stagni S; Torelli T; Agostini E; Celso F; Giannatempo P; Procopio G; Avuzzi B; Lanocita R; Cattaneo L; Catanzaro M; Biasoni D
    Tumori; 2023 Aug; 109(4):379-386. PubMed ID: 35915559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robotic-assisted retroperitoneal lymph node dissection for testicular cancer.
    Gereta S; Hung M; Hu JC
    Curr Opin Urol; 2023 Jul; 33(4):274-280. PubMed ID: 37014761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.